These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1424 related articles for article (PubMed ID: 26175403)
1. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403 [TBL] [Abstract][Full Text] [Related]
2. The role of MEK inhibitors in the treatment of metastatic melanoma. Grimaldi AM; Simeone E; Ascierto PA Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498 [TBL] [Abstract][Full Text] [Related]
4. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Richman J; Martin-Liberal J; Diem S; Larkin J Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
6. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
7. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658 [TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitors in cancer therapy. Hertzman Johansson C; Egyhazi Brage S Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952 [TBL] [Abstract][Full Text] [Related]
9. Targeting BRAF in melanoma: biological and clinical challenges. MandalĂ M; Voit C Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641 [TBL] [Abstract][Full Text] [Related]
10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
16. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830 [TBL] [Abstract][Full Text] [Related]